Filtered By:
Therapy: Chemotherapy
This page shows you your search results in order of date. This is page number 19.
Order by Relevance | Date
Total 70061 results found since Jan 2013.
Haploidentical Natural Killer Cell Therapy as an Adjunct to Stem Cell Transplantation for Treatment of Refractory Acute Myeloid Leukemia
Cell Transplant. 2023 Jan-Dec;32:9636897231198178. doi: 10.1177/09636897231198178.ABSTRACTRefractory acute myeloid leukemia (AML), defined as failure of two cycles of induction therapy at diagnosis or of one cycle at relapse, represents a subgroup with poor outcomes. Haploidentical natural killer cell (NK) therapy is a strategy that is being explored in refractory malignancies. Historically, at our center, patients with refractory AML have been treated with cytoreductive therapy (fludarabine + cytosine + granulocyte colony-stimulating factor ± idarubicin or mitoxantrone + etoposide) followed by 1-week rest and then reduce...
Source: Cell Transplantation - September 14, 2023 Category: Cytology Authors: Uday Kulkarni Arun Kumar Arunachalam Hamenth Kumar Palani Reeshma Radhakrishnan Nair Nithya Balasundaram Arvind Venkatraman Anu Korula Sushil Selvarajan Sharon Lionel Poonkuzhali Balasubramanian Madhavi Maddali Aby Abraham Biju George Vikram Mathews Source Type: research
Prognostic value of European Leukemia Net 2022 criteria and genomic clusters using machine learning in older adults with acute myeloid leukemia
This study aimed to validate the new European Leukemia Net (ELN) 2022 criteria for genetic risk stratification in older adults with acute myeloid leukemia (AML) and to determine the most likely set of clusters of similar cytogenetic and mutation properties correlated with survival outcomes in three treatment groups: intensive chemotherapy (IC), hypomethylating agents (HMAs) alone, and HMAs plus venetoclax (HMA/VEN). The study included 279 patients (≥60 years) who received IC (n=131), HMA (n=76), and HMA/VEN (n=72) between July 2017 and October 2021. No significant differences were observed in survival among the groups ac...
Source: Haematologica - September 14, 2023 Category: Hematology Authors: Silvia Park Tong Yoon Kim Byung-Sik Cho Daehun Kwag Jong-Mi Lee MyungShin Kim Yonggoo Kim Jamin Koo Anjali Raman Tae Kon Kim Hee-Je Kim Source Type: research
Daratumumab and brentuximab vedotin combination therapy in T-cell acute lymphoblastic leukemia refractory to conventional chemotherapy and allogeneic stem cell transplant
Haematologica. 2023 Sep 14. doi: 10.3324/haematol.2023.283740. Online ahead of print.ABSTRACTNot available.PMID:37706335 | DOI:10.3324/haematol.2023.283740
Source: Haematologica - September 14, 2023 Category: Hematology Authors: Kebede H Begna Nadine H Abdallah Michelle Janania-Martinez Abhishek A Mangaonkar Aruna Rangan Jennifer L Herrick Naseema Gangat Source Type: research
Outcome of conventional radiotherapy in small centrally located tumours or lymph nodes: minimal toxicity, remarkable survival but challenging loco-regional control
CONCLUSION: Conventional RT for patients with small central lung tumours or solitary lymph nodes is feasible. Median OS was 51 months, and toxicity was low with no grade 4-5 events.PMID:37707506 | DOI:10.1080/0284186X.2023.2257872
Source: Acta Oncologica - September 14, 2023 Category: Cancer & Oncology Authors: M M Knap S Khan A A Khalil D S M øller L Hoffmann Source Type: research
Prognostic value of European Leukemia Net 2022 criteria and genomic clusters using machine learning in older adults with acute myeloid leukemia
This study aimed to validate the new European Leukemia Net (ELN) 2022 criteria for genetic risk stratification in older adults with acute myeloid leukemia (AML) and to determine the most likely set of clusters of similar cytogenetic and mutation properties correlated with survival outcomes in three treatment groups: intensive chemotherapy (IC), hypomethylating agents (HMAs) alone, and HMAs plus venetoclax (HMA/VEN). The study included 279 patients (≥60 years) who received IC (n=131), HMA (n=76), and HMA/VEN (n=72) between July 2017 and October 2021. No significant differences were observed in survival among the groups ac...
Source: Haematologica - September 14, 2023 Category: Hematology Authors: Silvia Park Tong Yoon Kim Byung-Sik Cho Daehun Kwag Jong-Mi Lee MyungShin Kim Yonggoo Kim Jamin Koo Anjali Raman Tae Kon Kim Hee-Je Kim Source Type: research
Daratumumab and brentuximab vedotin combination therapy in T-cell acute lymphoblastic leukemia refractory to conventional chemotherapy and allogeneic stem cell transplant
Haematologica. 2023 Sep 14. doi: 10.3324/haematol.2023.283740. Online ahead of print.ABSTRACTNot available.PMID:37706335 | DOI:10.3324/haematol.2023.283740
Source: Haematologica - September 14, 2023 Category: Hematology Authors: Kebede H Begna Nadine H Abdallah Michelle Janania-Martinez Abhishek A Mangaonkar Aruna Rangan Jennifer L Herrick Naseema Gangat Source Type: research
Diffuse large B-cell lymphoma involving the central nervous system: biologic rationale for targeted therapy
Haematologica. 2023 Sep 14. doi: 10.3324/haematol.2021.278613. Online ahead of print.ABSTRACTDiffuse large B-cell lymphoma (DLBCL) is an aggressive B-cell lymphoma curable even in advanced stages. DLBCL involving the central nervous system (CNS) is more difficult to cure and fewer treatment options exist. Primary CNS lymphoma (PCNSL) refers to aggressive lymphomas confined to the CNS, and are almost always DLBCL. Standard approaches for PCNSL use high-dose methotrexate based combinations as induction therapy and younger patients often receive dose-intensive consolidation. However, dose-intensive therapies are not suitable ...
Source: Haematologica - September 14, 2023 Category: Hematology Authors: Mark Roschewski Daniel J Hodson Source Type: research
The Effects of High Deductible Health Plans on Breast Cancer Treatment and Reconstruction
CONCLUSION: The cost-sharing burden of HDHPs creates the potential for patients to forego care, and thus, effort should be directed toward increasing patient education concerning health plan benefits. Utilization of postdeductible spending, as well as resources of health savings accounts, may limit the adverse effects of HDHPs. This study also emphasizes the importance for providers to increase cost transparency.PMID:37709587 | DOI:10.1016/j.clbc.2023.08.006
Source: Clinical Genitourinary Cancer - September 14, 2023 Category: Cancer & Oncology Authors: Kaitlin D Jones Alexis C Lakatta Nicholas T Haddock Sumeet S Teotia Source Type: research
The Efficacy of Acupuncture in the Treatment of Chemotherapy-Induced Peripheral Neuropathy: A Network Meta-Analysis
CONCLUSION: After a comprehensive evaluation of 6 acupuncture therapies for treating CIPN based on NMA, electroacupuncture may be the best option for treating CIPN. However, would be more convincing to get evidence from more RCTs.PMID:37708563
Source: Alternative Therapies in Health and Medicine - September 14, 2023 Category: Complementary Medicine Authors: Teng Zhang Qiang Zhang Peiye Zhu Weidong Sun Zaiqiao Ding Lu Hu Source Type: research
Cladribine, Cytarabine, And Etoposide (CCE)-Based Regimens Are Safe and Tolerable In Relapsed And Refractory AML Patients
Acta Haematol. 2023 Sep 14. doi: 10.1159/000534024. Online ahead of print.ABSTRACTIntensive treatment regimens for relapsed/refractory (R/R) acute myeloid leukemia (AML) generally include an anthracycline, cytarabine, with or without a purine analogue. In patients who cannot tolerate an anthracycline due to comorbidities may consider using etoposide. Given the ongoing fludarabine shortage, it has prompted the switch to other purine analogues, such as cladribine, in combination with cytarabine and etoposide in patients who may be eligible for intensive chemotherapy but not able to tolerate an anthracycline due to comorbidit...
Source: Acta Haematologica - September 14, 2023 Category: Hematology Authors: Jose Tinajero Dat Ngo Amandeep Salhotra Paul Koller Source Type: research
Neoadjuvant triplet chemotherapy with docetaxel, cisplatin plus 5-FU vs docetaxel, cisplatin plus S-1 for advanced esophageal squamous cell carcinoma: Propensity score matched analysis
CONCLUSIONS: Neoadjuvant DCS therapy for resectable advanced ESCC did not result in significantly higher clinical and pathological response than neoadjuvant DCF therapy. However, neoadjuvant DCS therapy for resectable ESCC required comparatively shorter hospital stays and incurred lower costs, making it an attractive therapeutic option.PMID:37708864 | DOI:10.1159/000533790
Source: Oncology - September 14, 2023 Category: Cancer & Oncology Authors: Junya Kitadani Toshiyasu Ojima Keiji Hayata Taro Goda Akihiro Takeuchi Shinta Tominaga Naoki Fukuda Tomoki Nakai Hiroki Yamaue Manabu Kawai Source Type: research
Host cell environments and antibiotic efficacy in tuberculosis
Trends Microbiol. 2023 Sep 12:S0966-842X(23)00253-6. doi: 10.1016/j.tim.2023.08.009. Online ahead of print.ABSTRACTThe aetiologic agent of tuberculosis (TB), Mycobacterium tuberculosis (Mtb), can survive, persist, and proliferate in a variety of heterogeneous subcellular compartments. Therefore, TB chemotherapy requires antibiotics crossing multiple biological membranes to reach distinct subcellular compartments and target these bacterial populations. These compartments are also dynamic, and our understanding of intracellular pharmacokinetics (PK) often represents a challenge for antitubercular drug development. In recent ...
Source: Trends in Microbiology - September 14, 2023 Category: Microbiology Authors: Nathan J Day Pierre Santucci Maximiliano G Gutierrez Source Type: research
Impact of Sodium Thiosulfate on Prevention of Nephrotoxicities in HIPEC: An Ancillary Evaluation of Cisplatin-Induced Toxicities in Ovarian Cancer
CONCLUSIONS: ST significantly reduces acute renal toxicity associated with HIPEC with cisplatin in ovarian cancer patients. As nephrotoxicity is high in HIPEC with cisplatin, nephroprotective agents should be considered.PMID:37710139 | DOI:10.1245/s10434-023-14216-6
Source: Ann Oncol - September 14, 2023 Category: Cancer & Oncology Authors: Rosemary N Senguttuvan Nicole Lugo Santiago Ernest S Han Byrne Lee Stephen Lee Wei-Chien Lin Mehdi Kebria Amy Hakim Jeff F Lin Mark T Wakabayashi Nora Ruel Raechelle Tinsley Melissa Eng Daphne B Stewart Edward W Wang Benjamin I Paz Xiwei Wu Hyejin Cho Win Source Type: research
Outcome of conventional radiotherapy in small centrally located tumours or lymph nodes: minimal toxicity, remarkable survival but challenging loco-regional control
CONCLUSION: Conventional RT for patients with small central lung tumours or solitary lymph nodes is feasible. Median OS was 51 months, and toxicity was low with no grade 4-5 events.PMID:37707506 | DOI:10.1080/0284186X.2023.2257872
Source: Acta Oncologica - September 14, 2023 Category: Cancer & Oncology Authors: M M Knap S Khan A A Khalil D S M øller L Hoffmann Source Type: research
